SMT202600118T1 - C5ar1 inibitori per il trattamento di reazioni di ipersensibilità ai taxani - Google Patents

C5ar1 inibitori per il trattamento di reazioni di ipersensibilità ai taxani

Info

Publication number
SMT202600118T1
SMT202600118T1 SM20260118T SMT202600118T SMT202600118T1 SM T202600118 T1 SMT202600118 T1 SM T202600118T1 SM 20260118 T SM20260118 T SM 20260118T SM T202600118 T SMT202600118 T SM T202600118T SM T202600118 T1 SMT202600118 T1 SM T202600118T1
Authority
SM
San Marino
Prior art keywords
c5ar1
taxanes
inhibitors
hypersensitivity reactions
treating hypersensitivity
Prior art date
Application number
SM20260118T
Other languages
English (en)
Italian (it)
Inventor
Laura Brandolini
Andrea Aramini
Marcello Allegretti
Anna Sirico
Piergiorgio Amendola
Maria Candida Cesta
Original Assignee
Dompe Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21163292.2A external-priority patent/EP4059497A1/en
Application filed by Dompe Farm Spa filed Critical Dompe Farm Spa
Publication of SMT202600118T1 publication Critical patent/SMT202600118T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SM20260118T 2021-03-17 2022-03-17 C5ar1 inibitori per il trattamento di reazioni di ipersensibilità ai taxani SMT202600118T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21163292.2A EP4059497A1 (en) 2021-03-17 2021-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP21217382 2021-12-23
EP22716203.9A EP4308114B1 (en) 2021-03-17 2022-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
PCT/EP2022/057007 WO2022195017A1 (en) 2021-03-17 2022-03-17 C5ar1 inhibitors for treating hypersensitivity reactions to taxanes

Publications (1)

Publication Number Publication Date
SMT202600118T1 true SMT202600118T1 (it) 2026-05-12

Family

ID=81307212

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20260118T SMT202600118T1 (it) 2021-03-17 2022-03-17 C5ar1 inibitori per il trattamento di reazioni di ipersensibilità ai taxani

Country Status (15)

Country Link
US (1) US20240180888A1 (cg-RX-API-DMAC7.html)
EP (1) EP4308114B1 (cg-RX-API-DMAC7.html)
JP (1) JP2024512472A (cg-RX-API-DMAC7.html)
BR (1) BR112023018826A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212816A1 (cg-RX-API-DMAC7.html)
DK (1) DK4308114T3 (cg-RX-API-DMAC7.html)
FI (1) FI4308114T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20260351T1 (cg-RX-API-DMAC7.html)
IL (1) IL305727A (cg-RX-API-DMAC7.html)
LT (1) LT4308114T (cg-RX-API-DMAC7.html)
PL (1) PL4308114T3 (cg-RX-API-DMAC7.html)
RS (1) RS67911B1 (cg-RX-API-DMAC7.html)
SI (1) SI4308114T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202600118T1 (cg-RX-API-DMAC7.html)
WO (1) WO2022195017A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202543631A (zh) * 2024-03-14 2025-11-16 美商凡況生化公司 嗒嗪酮c5ar1拮抗劑及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002500667A (ja) * 1997-05-27 2002-01-08 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド 人間の患者に対して経口的にタキサン類を投薬するための方法及び組成物
DE69828615T2 (de) * 1997-10-31 2005-12-01 Walter Reed Army Institute Of Research Verwendung von inhibitoren der komplementaktivierung zur herstellung eines medikaments zur inhibierung von nebenwirkungen von pharmazeutischen zusammensetzungen, die amphiphile träger oder wirkstoffträger moleküle enthalten
RU2002113659A (ru) * 1999-10-27 2004-01-27 Бейкер Нортон Фармасьютикалз, Инк. (Us) Способ и композиции для перорального введения таксанов больным людям
JP5374157B2 (ja) * 2005-11-24 2013-12-25 ドムペ・ファ.ル.マ・ソチエタ・ペル・アツィオーニ (r)−アリールアルキルアミノ誘導体類と、それらを含有する薬剤組成物
EP3498269A1 (en) * 2017-12-12 2019-06-19 Dompé farmaceutici S.p.A. C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain

Also Published As

Publication number Publication date
US20240180888A1 (en) 2024-06-06
PL4308114T3 (pl) 2026-05-04
EP4308114B1 (en) 2026-02-11
RS67911B1 (sr) 2026-04-30
EP4308114A1 (en) 2024-01-24
WO2022195017A1 (en) 2022-09-22
FI4308114T3 (fi) 2026-03-25
DK4308114T3 (da) 2026-03-23
IL305727A (en) 2023-11-01
JP2024512472A (ja) 2024-03-19
LT4308114T (lt) 2026-03-25
CA3212816A1 (en) 2022-09-22
BR112023018826A2 (pt) 2024-03-12
HRP20260351T1 (hr) 2026-04-24
SI4308114T1 (sl) 2026-05-29

Similar Documents

Publication Publication Date Title
ES3065663T3 (en) C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
IL254131A0 (en) Fidi-1 / Fidi-AL1 inhibitors for cancer treatment
SG10202011110PA (en) Methods of treating skin cancer by administering a pd-1 inhibitor
ZA201708685B (en) Mixture for treating fertilisers containing urea
ZA201803530B (en) Compounds and compositions useful for treating disorders related to ntrk
ZA201801881B (en) Compounds and compositions useful for treating disorders related to ntrk
BR112014029404A2 (pt) compostos , composição farmacêutica, utilização de um composto, método para o tratamento ou profilaxia do cancêr e invenção
EP2717870A4 (en) COMPOUNDS AND COMPOSITIONS FOR STABILIZING THE HYPOXIA-INDUCIBLE FACTOR-2 ALPHA AS METHOD FOR THE TREATMENT OF CANCER
MX348311B (es) Inhibidores nampt.
SG11202105531XA (en) Methods for treating cancer resistant to cdk4/6 inhibitors
PL2920133T3 (pl) Kompozycja do zaprawiania korzeni roślin
IL287210A (en) Preparations for the treatment of tumors
PL2694073T3 (pl) Kombinacje inhibitorów AKT i MEK do leczenia nowotworu
PT3703747T (pt) Utilização de um inibidor de nox4 ou nox4/1 em combinação com um agente imunoterapêutico para o tratamento do cancro
IL316829A (en) Menin-MLL inhibitors for cancer treatment
PL4308114T3 (pl) Inhibitory c5ar1 do leczenia reakcji nadwrażliwości na taksany
IL289811A (en) A method for treating cancer
IL289201A (en) Compounds for the treatment of cancer
IL288665A (en) Methods for treating cancer using prmt5 inhibitors
IL288003A (en) Cancer treatment methods using chk1 inhibitors
HK40097618A (en) C5ar1 inhibitors for treating hypersensitivity reactions to taxanes
EP3313866A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER AND PROMOTING WOUND HEALING
IL310851A (en) Compounds for the treatment of diseases associated with PCSK9 activity
PT4308114T (pt) Inibidores de c5ar1 para o tratamento de reações de hipersensibilidade a taxanos
IL308424A (en) Use of Pleversiv to treat anemia